| Pruitthealth - Magnolia Manor | |
| 3003 Veterans Parkway S, Moultrie, Georgia 31788 | |
| (229) 985-3422 | |
| Name | Pruitthealth - Magnolia Manor |
|---|---|
| Location | 3003 Veterans Parkway S, Moultrie, Georgia |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 100 |
| Occupancy Rate | 70% |
| Medicare ID (CCN) | 115326 |
| Legal Business Name | Pruitthealth - Magnolia Manor Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1982651402 |
| Organization Name | PRUITTHEALTH - MAGNOLIA MANOR, LLC |
| Doing Business As | PRUITTHEALTH - MAGNOLIA MANOR |
| Address | 3003 Veterans Parkway South, Moultrie, GA 31788 |
| Phone Number | 229-985-3422 |
News Archive
"The Obama administration and Congress should continue efforts to strengthen the safety of America's drug supply and, simultaneously, coordinate a global response to the problem of counterfeit drugs," Thomas Kubic, president & CEO of the Pharmaceutical Security Institute and a former deputy assistant director at the FBI, writes in a post on The Hill's "Congress Blog," where he describes the health risks associated with such drugs.
The U.S. Food and Drug Administration today approved the cobas Zika test, a qualitative nucleic acid test for the detection of Zika virus RNA in individual plasma specimens obtained from volunteer donors of whole blood and blood components, and from living organ donors.
The Institute of Materia Medica (IMM), a member of the Chinese Academy of Medical Sciences, and the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership accelerating the discovery and development of new TB drugs, today announced plans to pursue a joint research partnership to develop promising, novel anti-tuberculosis agents.
Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, with further development undertaken by Sanofi-Aventis and Sanofi-Pasteur. The collaboration will initially involve two targets nominated by Sanofi-Aventis and Sanofi-Pasteur, and includes the option for four additional targets.
A Northwestern University Feinberg School of Medicine researcher has launched the first U.S. trial in which a purified form of subjects' own adult stem cells was transplanted into their leg muscles with severely blocked arteries to try to grow new small blood vessels and restore circulation in their legs.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
"The Obama administration and Congress should continue efforts to strengthen the safety of America's drug supply and, simultaneously, coordinate a global response to the problem of counterfeit drugs," Thomas Kubic, president & CEO of the Pharmaceutical Security Institute and a former deputy assistant director at the FBI, writes in a post on The Hill's "Congress Blog," where he describes the health risks associated with such drugs.
The U.S. Food and Drug Administration today approved the cobas Zika test, a qualitative nucleic acid test for the detection of Zika virus RNA in individual plasma specimens obtained from volunteer donors of whole blood and blood components, and from living organ donors.
The Institute of Materia Medica (IMM), a member of the Chinese Academy of Medical Sciences, and the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership accelerating the discovery and development of new TB drugs, today announced plans to pursue a joint research partnership to develop promising, novel anti-tuberculosis agents.
Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, with further development undertaken by Sanofi-Aventis and Sanofi-Pasteur. The collaboration will initially involve two targets nominated by Sanofi-Aventis and Sanofi-Pasteur, and includes the option for four additional targets.
A Northwestern University Feinberg School of Medicine researcher has launched the first U.S. trial in which a purified form of subjects' own adult stem cells was transplanted into their leg muscles with severely blocked arteries to try to grow new small blood vessels and restore circulation in their legs.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 23.96 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.56 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 31.25 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.23 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 7.59 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.47 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.1 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.56 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 16.67 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.51 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.95 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 43.42 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 26.5 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 12.75 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.57 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 80.56 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 87.45 | 82.93 |
News Archive
"The Obama administration and Congress should continue efforts to strengthen the safety of America's drug supply and, simultaneously, coordinate a global response to the problem of counterfeit drugs," Thomas Kubic, president & CEO of the Pharmaceutical Security Institute and a former deputy assistant director at the FBI, writes in a post on The Hill's "Congress Blog," where he describes the health risks associated with such drugs.
The U.S. Food and Drug Administration today approved the cobas Zika test, a qualitative nucleic acid test for the detection of Zika virus RNA in individual plasma specimens obtained from volunteer donors of whole blood and blood components, and from living organ donors.
The Institute of Materia Medica (IMM), a member of the Chinese Academy of Medical Sciences, and the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership accelerating the discovery and development of new TB drugs, today announced plans to pursue a joint research partnership to develop promising, novel anti-tuberculosis agents.
Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, with further development undertaken by Sanofi-Aventis and Sanofi-Pasteur. The collaboration will initially involve two targets nominated by Sanofi-Aventis and Sanofi-Pasteur, and includes the option for four additional targets.
A Northwestern University Feinberg School of Medicine researcher has launched the first U.S. trial in which a purified form of subjects' own adult stem cells was transplanted into their leg muscles with severely blocked arteries to try to grow new small blood vessels and restore circulation in their legs.
› Verified 3 days ago
Pruitthealth - Magnolia Manor Location: 3003 Veterans Parkway S, Moultrie, Georgia 31788 Phone: (229) 985-3422 | |
Cobblestone Rehabilitation And Healthcare Center Location: 101 Cobblestone Trace Se, Moultrie, Georgia 31768 Phone: (229) 985-3637 | |